

## Product Information

**Size:**

50ul

**Reactivity:**

Human, Mouse

**Source:**

Rabbit

**Isotype:**

IgG

**Applications:**

ELISA, IHC

**Recommended dilutions:**

ELISA:1:1000-1:2000, IHC:1:25-1:100

**Protein Background:**

Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones.

**Gene ID:**

PRAF2

**Uniprot**

O60831

**Synonyms:**

PRA1 domain family, member 2

**Immunogen:**


Synthetic peptide of human PRAF2.

**Storage:**


-20&deg; C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

## Product Images

---



The image on the left is immunohistochemistry of paraffin-embedded Human colon cancer tissue using PACO20374(PRAF2 Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: x—200).



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO20374(PRAF2 Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: x—200).